Author

B. L. Innis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Organism:non-human primate· 2 Organism:rat· 2 Assay:proteomics· 1

Frequent Co-Authors

A. Garcia-Sastre· 2 shared F. Amanat· 2 shared F. Krammer· 2 shared P. Palese· 2 shared S. McCroskery· 2 shared S. Slamanig· 2 shared W. Sun· 2 shared Y. Liu· 2 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Garcia-Sastre

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters

W. Sun, Y. Liu, F. Amanat, I. Gonzalez-Dominguez, S. McCroskery, S. Slamanig, L. Coughlan, V. Rosado, N. Lemus, S. Jangra, R. Rathnasinghe, M. Schotsaert, J. Martinez, K. Sano, I. Mena, , P. Palese

This study develops a Newcastle disease virus-based vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein, showing strong immune responses and cross-neutralization against variants in mice and hamsters.

bioRxiv · Jul 6, 2021 · PreprintImmunology

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

W. Sun, S. McCroskery, W.-C. Liu, S. R. Leist, Y. Liu, R. A. Albrecht, S. Slamanig, J. Oliva, F. Amanat, A. Schaefer, K. H. Dinnon, B. L. Innis, A. Garcia-Sastre, F. Krammer, R. S. Baric, P. Palese

This paper evaluates an inactivated Newcastle disease virus expressing the SARS-CoV-2 spike protein as a cost-effective vaccine, showing immunogenicity and protective efficacy in animal models.

bioRxiv · Jul 30, 2020Microbiology